Add Formweb to your mobile device
Search results for:
OLANZapine
OLANZapine
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Olanzapine | POWDER FOR INJECTION, INTRAMUSCULAR | 10 mg | |
| Olanzapine | TABLET, DISINTEGRATING, ORAL | 5 mg | |
| Olanzapine | TABLET, DISINTEGRATING, ORAL | 10 mg | |
| Olanzapine | TABLET, ORAL | 2.5 mg | |
| Olanzapine | TABLET, ORAL | 5 mg | |
| Olanzapine | TABLET, ORAL | 7.5 mg | |
| Olanzapine | TABLET, ORAL | 10 mg | |
| Olanzapine | TABLET, ORAL | 15 mg | |
| Olanzapine | TABLET, ORAL | 20 mg | |
| Zyprexa |
Last updated: Oct. 17, 2023
- Black Box Warning: Mortality in elderly with dementia related psychosis
- REMS: Zyperexa Relprew Extended Relaease Injection
control (often in your face, tongue or jaw)
Injectable olanzapine given intravenous (IV) is an off-label route. It is only labeled for intramuscular (IM) use.
Adverse reactions with olanzapine IM and IV may include: dizziness, drowsiness, postural hypotension, bradycardia, and respiratory depression.
Monitor the patient closely. If dizziness and/or drowsiness are noted, the patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem
Olanzapine IM/IV 10 mg (Zyprexa): reconstitute with 2.1 mL sterile water. Final concentration = 5 mg/mL. Use immediately after reconstitution. See Package Insert.
Use for delirium in a ventilated Critical Care patient: See Guideline 901.5008